Filter posts

Alzheimer’s Research: Where We’ve Failed and What’s To Come

Alzheimer’s disease is a rapidly growing public health crisis. Today an estimated 5.4 million Americans …

Is Immunotherapy the 4th Pillar of Oncology?

In contrast to the three traditional pillars of cancer treatment (surgery, radiotherapy, and chemotherapy), cancer …

Health Affairs: Burden of Vaccine-Preventable Diseases

Just as flu season gears up, Health Affairs released a new study, “Modeling The Economic …

Five Oncologists Weigh in on Value Frameworks

Value Frameworks, which attempt to quantify the value of a medicine, have been a hot …

BIO Investor Forum Session on Advancing Immuno–Oncology

At the 2016 BIO Investor Forum, the first session held was titled “The Intersection of …

Lawsuit Against UnitedHealth Put Insurers’ Practices Under Scrutiny

Reuters reports that UnitedHealth Group, the nation’s largest insurer, has been sued by three patients …

Astellas Expands Advocacy Engagement with Focused Outreach

Astellas recognizes the crucial role that patient groups play in enhancing and extending the lives …

Closing the Gender Gap in Biotech through SBIR/STTR Funding

Although progress has been made, there is no denying the biotech industry continues to have …

Riding Coast to Coast for Cancer Patients

For 21 days in September, 80 members of Bristol-Myers Squibb’s (BMS) oncology team will cross …

Cancer Docs Weigh in on Medicare Part B Demo

This week, American Society of Clinical Oncology (ASCO) President Daniel Hayes, MD and CEO Clifford …